-
公开(公告)号：KR1020170027613A
公开(公告)日：2017-03-10
申请号：KR1020150124462
申请日：2015-09-02
Applicant: 한국과학기술연구원
IPC: C01B31/02
CPC classification number: C09K11/65 , C01B32/15 , C01P2004/62 , C01P2004/64 , C09K11/68 , C09K11/7756 , C09K11/7759 , C09K11/87
Abstract: 유기용매의분해생성물인복수개의유기분자들을포함하는탄소나노구조체및 이의제조방법이제공된다. 해당탄소나노구조체는분해되는용매의특성에따라다양한특성을가질수 있으며, 도핑된이종원소의종류에따라다양한특성을보일수 있어이를다양한분야에적용할수 있다. 또한, 해당탄소나노구조체는유기용매를단독으로사용하여합성되기때문에부반응의생성이억제될수 있으므로, 정제공정없이고품질을갖도록형성될수 있다. 더불어, 해당탄소나노구조체를형성한후 남은잔여용매는추출하여재활용이가능하며이를통해폐기물이발생하지않는친환경적공정이가능할수 있다.
Abstract translation: 提供了包含作为有机溶剂的分解产物的多个有机分子的碳纳米结构体。 碳纳米结构包括碳纳米结构芯和结合并生长在碳纳米结构芯上的多个有机分子，其中碳纳米结构芯是有机分子的组合。
-
公开(公告)号：KR1020170027612A
公开(公告)日：2017-03-10
申请号：KR1020150124461
申请日：2015-09-02
Applicant: 한국과학기술연구원
Abstract: 적층구조를갖는 3차원재료의양자점으로서, 이종원소가도핑된그래핀양자점, 이종원소가도핑된보론나이트라이드또는이종원소가도핑된무기칼코게나이드양자점인이종원소가도핑된 3차원재료의양자점이제공된다. 해당이종원소를포함하는분자가도핑된 3차원재료의양자점은박리재, 도핑용기체또는유기물의주입없이형성되므로품질이우수할수 있으며여러색을구현할수 있으고, 발광특성이우수하고반도체적성질과전기적성질을향상시킬수 있는이종원소가도핑되어있으므로반도체소자, 에너지소자또는발광소자등에다양한분야에응용될수 있다.
-
公开(公告)号：KR100296250B1
公开(公告)日：2001-10-25
申请号：KR1019980012818
申请日：1998-04-10
Applicant: 한국과학기술연구원
IPC: A61K36/725 , A61K36/752 , A61P3/06 , A61P9/12
Abstract: PURPOSE: A composition containing a jujube extract and a tangerine pericarp extract containing naringin and hesperidin is provided which has an effect on prevention of adult diseases and cancer such as liver diseases, hypertension, arteriosclerosis, hyperlipidemia or the like when administered to animals. CONSTITUTION: This composition comprises a jujube extract and hesperidin, hesperetin, naringin, naringenin or a mixture thereof as flavonoid originated from a tangerine pericarp extract in a weight ratio of 1:0.001 to 1:0.1. For an example, 5kg jujube is extracted with 15L water at 100deg.C for 2hr two times, followed by filtering. The filtrate is then concentrated under reduced pressure to produce 2kg extract. And 500g tangerine is extracted with 5L ethanol at 60deg.C for 5 hr to produce 190g extract. The jujube extract and tangerine pericarp extract can be orally or parenterally administered at a dose of 0.1 to 5g, preferably 0.5 to 1g and 0.1 to 10g, preferably 0.5 to 2g/kg.weight.day respectively.
-
4.发明公开네오헤스페리딘디하이드로칼콘을포함하는동맥경화증,고지혈증,간질환,고혈당증의예방및치료용조성물 失效包含NEOHESPERIDIN DIHYDROCHALCONE的组合物，用于预防和治疗高脂血症，肠梗塞，肝病和高血压
公开(公告)号：KR1020000019720A
公开(公告)日：2000-04-15
申请号：KR1019980037963
申请日：1998-09-15
Applicant: 한국과학기술연구원
Abstract: PURPOSE: A pharmaceutical composition and functional food and drink comprising neohesperid in dihydrochalcone are provided, for treating and preventing hyper lipidemia, arteriosclerosis, a liver disease and hyperglycemia. CONSTITUTION: The pharmaceutical composition comprises neohesperid in dihydrochalcone ineffective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of neohesperid in dihydrochalcone. Neohesperidin dihydrochalcone reduces the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase) and a lipid in blood, inhibits HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester, and inhibits the damage of a liver cell and the formation of a fatty liver. Also neohesperid in dihydrochalcone strongly inhibits the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface, and reduces the concentration of blood sugar.
Abstract translation: 目的：提供一种包含二氢查耳酮中新月皮的药物组合物和功能性食品和饮料，用于治疗和预防高脂血症，动脉硬化，肝脏疾病和高血糖症。 组成：药物组合物含二氢查耳酮中的新皮肤无效量; 和药学上可接受的载体。 功能性食品或饮料包含二氢查耳酮中的新鲜皮肤的0.01-20重量％，优选0.1-5重量％。 新橙皮苷二氢查耳酮降低血清GOT（谷氨酸 - 草酰乙酸转氨酶），GPT（谷氨酸 - 丙酮酸转氨酶）和血液中的脂质的浓度，抑制与生物合成相关的还原酶的HMG CoA（3-羟基-3-甲基戊二酰辅酶） 的胆固醇和ACAT（酰基CoA;胆固醇-O-酰基转移酶），其将胆固醇转化为胆固醇酯，并且抑制肝细胞的损伤和脂肪肝的形成。 二氢查耳酮中的新生皮肤也强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面，并降低血糖浓度。
-
公开(公告)号：KR1020000019716A
公开(公告)日：2000-04-15
申请号：KR1019980037958
申请日：1998-09-15
Applicant: 한국과학기술연구원
IPC: A61K31/70
CPC classification number: A61K31/34 , Y10S514/866
Abstract: PURPOSE: A pharmaceutical composition and a functional food comprising bioflavonoid compounds are provided, for descending blood sugar. CONSTITUTION: The pharmaceutical composition comprises the bioflavonoid compounds represented by the formula 1 in effective amount; and pharmaceutically acceptable carriers. In the formula 1, R¬1 represents OH, rutinosyl or rhaminosyl group, R¬2 represents H, OH or rutinosyl group, R¬3 represents H or OH group, R¬4 represents OH or method group, and X represents a single bond or a double bond. The functional food comprises 0.01-50 wt%, preferably 0.05-10 wt% of the bioflavonoid compounds. The compounds of the formula 1 descends blood sugar, and therefore can be used for treating or preventing hyperglycemia.
Abstract translation: 目的：提供包含生物类黄酮化合物的药物组合物和功能性食品，用于降血糖。 构成：药物组合物包含有效量的式1所示的生物类黄酮化合物; 和药学上可接受的载体。 在式1中，R 1表示OH，芸香酰基或脱氨基糖基，R 2表示H，OH或芸香糖基，R 3表示H或OH基，R 4表示OH或方法基，X表示单 债券或双重债券。 功能性食品包含0.01-50重量％，优选0.05-10重量％的生物类黄酮化合物。 式1的化合物降低血糖，因此可用于治疗或预防高血糖症。
-
Patent Agency Ranking
-
公开(公告)号：KR1019990076178A
公开(公告)日：1999-10-15
申请号：KR1019980010888
申请日：1998-03-28
Applicant: 한국과학기술연구원
IPC: A61K31/7048 , A61P1/16
Abstract: 본 발명은 헤스페리딘(hesperidin)을 포함하는 간 질환의 예방 및 치료용 조성물에 관한 것으로, 본 발명의 조성물은 의약용 및 식품용 조성물을 포함한다. 헤스페리딘은 동물에게 투여되었을 때 혈청 GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase) 및 γGTP(γ-glutamyl transpeptidase)의 농도를 강하시키므로 본 발명의 조성물은 각종 간 질환의 예방 및 치료제로서 유용하게 사용될 수 있다.
-
8.发明公开네오헤스페리딘 디하이드로칼콘을 포함하는 동맥경화증,고지혈증, 간 질환, 고혈당증의 예방 및 치료용 조성물 失效含有NEOHESPERIDIN DIHYDROCHALCONE的组合物可用于预防和治疗ARTERIOSCLEROSIS，HYPERLIPEMIA，肝脏疾病和GLYCOSEMIA
公开(公告)号：KR1020010007624A
公开(公告)日：2001-01-26
申请号：KR1020000058788
申请日：2000-10-06
Applicant: 한국과학기술연구원
IPC: A61K31/70
Abstract: PURPOSE: A composition containing neohesperidin dihydrochalcone generally used as a sweetener is provided for preventing and treating arteriosclerosis, hyperlipemia, liver diseases, and glycosemia. CONSTITUTION: Neohesperidin dihydrochalcone(C28H36O15, M.W. 612.60) is obtained by extracting from the rind or outer layer of grapefruit or by chemically changing Naringin, and it is sweeter 1,500 to 2,000 times than sugar per unit weight. Therefore it has been usually used as a sweetener not a medicinal material. The composition containing an effective amount of neohesperidin dihydrochalcone, that is, 0.1 to 500 mg/kg, preferably 1 to 100 mg/kg a day, is orally or topically administrated into a patient and the amount of administration may be variable by patient's age, weight, sex, health, diet, severity of disease, and so on. The composition containing neohesperidin dihydrochalcone may be added into foods and drinks in an amount of 0.01 to 20 wt.%, preferably 0.1 to 5 wt.% of diosmin.
Abstract translation: 目的：提供通常用作甜味剂的含有新皮质激素二氢查耳酮的组合物，用于预防和治疗动脉硬化，高脂血症，肝脏疾病和糖血症。 构成：通过从葡萄柚的外层或外层提取或通过化学改变柚皮苷获得新的皮肤色素二氢查耳酮（C28H36O15，M.W.612.60），并且比单位重量的糖更甜1,500-2000倍。 因此，它通常用作不是药用材料的甜味剂。 将包含有效量的新橙皮苷二氢查耳酮，即0.1至500mg / kg，优选1至100mg / kg每天的组合物口服或局部施用于患者，并且施用量可以由患者的年龄， 体重，性别，健康，饮食，疾病严重程度等。 含有新橙皮苷二氢查耳酮的组合物可以以diosmin的0.01〜20重量％，优选0.1〜5重量％的量添加到食品和饮料中。
-
9.发明公开탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물 无效包含从鞣剂衍生的鞣制或酚醛化合物的组合物，用于预防和治疗高脂血症，肠梗塞和肝病
公开(公告)号：KR1020000019718A
公开(公告)日：2000-04-15
申请号：KR1019980037961
申请日：1998-09-15
Applicant: 한국과학기술연구원
IPC: A61K31/045
CPC classification number: A23G3/368 , A21D2/14 , A21D2/145 , A21D2/181 , A21D2/36 , A23C9/152 , A23F3/14 , A23L2/56 , A23L33/105 , A61K31/70 , Y10S514/824 , A61K31/35 , A61K31/19 , A61K2300/00
Abstract: PURPOSE: A pharmaceutical composition and functional food and drink comprising tannin or phenol-type compounds derived from tannin are provided, for treating and preventing hyper lipidemia, arteriosclerosis and a liver disease. CONSTITUTION: The pharmaceutical composition comprises tannin, gallic acid, ellagic acid or their mixture in effective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of tannin, gallic acid, ellagic acid or their mixture. Tannin, gallic acid and ellagic acid reduce the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase), gamma GTP (gamma-glutamyl transpeptidase) and a lipid in blood, and inhibit the damage of a liver cell and the formation of a fatty liver. Also tannin, gallic acid and ellagic acid strongly inhibit the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface.
Abstract translation: 目的：提供包含单宁衍生的单宁或酚型化合物的药物组合物和功能性食品和饮料，用于治疗和预防高脂血症，动脉硬化和肝脏疾病。 构成：药物组合物含有有效量的单宁，没食子酸，鞣花酸或其混合物; 和药学上可接受的载体。 功能性食品或饮料包含0.01-20重量％，优选0.1-5重量％的单宁，没食子酸，鞣花酸或其混合物。 单宁，没食子酸和鞣花酸降低血清GOT（谷氨酸 - 草酰乙酸转氨酶），GPT（谷氨酸 - 丙酮酸转氨酶），γGTP（γ-谷氨酰转肽酶）和血脂中的血清浓度，抑制肝细胞损伤 并形成脂肪肝。 单宁，没食子酸和鞣花酸强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面。
-
公开(公告)号：KR100291141B1
公开(公告)日：2001-07-12
申请号：KR1019980037962
申请日：1998-09-15
Applicant: 한국과학기술연구원
IPC: A61K31/70
Abstract: 본 발명은 디오스민(diosmin)을 포함하는 동맥경화증 및 고지혈증의 예방 및 치료용 조성물에 관한 것으로, 디오스민은 동물에게 투여되었을 때 동맥내피에 대식세포-지질 복합체가 침착되는 것을 강력히 억제할 뿐만 아니라, ACAT 및 HMG-CoA 환원효소의 활성을 억제하고, 혈중 콜레스테롤 및 중성지질의 농도를 감소시키므로, 동맥경화증 및 고지혈증의 예방 및 치료제로서 유용하게 사용될 수 있다.
-
-
-
-
-
-
-
-
-
Search Results
35
records
(took 0.026 seconds)
